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Abstract
Objectives—To assess the performance of three risk scores from Japan that were developed to
predict, in children with Kawasaki disease, resistance to intravenous immunoglobulin (IVIG)
treatment.
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Study design—We used data from a randomized trial of pulsed steroids for primary treatment
of Kawasaki disease to assess operating characteristics of the three risk scores, and we examined
whether steroid therapy lowers the risk of coronary artery abnormalities in patients prospectively
classified as IVIG resistant.
Results—For comparability with published cohorts, we analyzed the data of 99 patients not
treated with steroids (16% IVIG-retreated), and identified male sex, lower albumin and higher
AST as independent risk factors for IVIG resistance. The Kobayashi score was similar in IVIGresistant and responsive patients, yielding sensitivity=33% and specificity=87%. There was no
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interaction of high vs. low risk status by treatment received (steroid vs. placebo) using any of the
three risk score algorithms.
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Conclusion—Risk scoring systems from Japan have good specificity but low sensitivity for
predicting IVIG resistance in a North American cohort. Primary steroid therapy did not improve
coronary outcomes among patients prospectively classified as high risk for IVIG resistance.
Keywords
Kawasaki; pediatrics; inflammation; therapy
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Administration of intravenous immunoglobulin (IVIG) in the first 10 days after onset of
Kawasaki disease (KD) lowers the prevalence of coronary artery (CA) aneurysms. However,
most studies indicate that 13% to 21% of patients have IVIG resistance, that is, recrudescent
or persistent fever after completion of initial IVIG administration1–4. Children with IVIG
resistance are at higher risk for development of CA aneurysms.5–6 The identification of this
high-risk subset at the time of presentation might identify patients who would benefit from
primary treatment regimens combining IVIG with other anti-inflammatory therapies, such as
tumor necrosis factor α (TNF-α) antagonists. Recent research has focused on identification
of predictors of IVIG resistance, and risk scoring algorithms have been developed to
estimate a patient's likelihood of successful treatment with single, high-dose IVIG1–3,5 We
used the dataset of the Pediatric Heart Network KD Trial cohort to 1) assess the operating
characteristics of the published Japanese risk scoring systems in a North American
population; 2) examine whether risk level defined by the scoring systems is predictive of the
occurrence of CA abnormalities, and 3) assess whether primary steroid therapy can be
demonstrated as effective in patients who are predicted to be at high risk of IVIG resistance
based upon factors that are known at the time of presentation.

METHODS
We enrolled patients in a randomized, double-blind, placebo-controlled trial of pulsed
corticosteroid therapy for primary treatment of KD from December 2002 to December 2004
at eight clinical centers in North America. The entry criteria, methods and results of the trial
have been previously published.8 Enrolled patients met modified American Heart
Association criteria for KD and were between days four and ten of illness9. The study was
conducted in accordance with Institutional Review Board approval at each participating
center. A parent or guardian of each subject provided written informed consent. The study is
registered with clinicaltrials.gov: NCT00132080.
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Randomization was stratified by age (< 1 year vs. ≥ 1 year) and sex, with dynamic balancing
by center. Patients were randomly assigned to receive either IV methylprednisolone (IVMP),
30 mg/kg over 2–3 hours, or placebo infusion of 5% Dextrose in Water in a similar volume
and over the same time period as the infusion of IVMP. Each subject, regardless of random
treatment assignment, also received IVIG (2 g/kg) and aspirin, 80 to 100 mg/kg/day, until
afebrile for 48 hours, then 3 to 5 mg/kg once daily until five weeks post-randomization.
Subjects with fever of at least 38.3°C without another likely source at >3 6 hours after
completion of the initial IVIG treatment were retreated with IVIG, 2 g/kg. A second
retreatment (i.e., a third treatment) with IVIG, 2 g/kg, was administered to subjects with
recrudescent or persistent fever without another source >36 hours after IVIG retreatment.
Echocardiograms and laboratory data were obtained at baseline (prior to treatment) and at
one and five weeks post-randomization. All measurements were used in this analysis even if
outside of the protocol-allowed measurement window. Dimensions of the left main coronary
artery (LMCA), proximal left anterior coronary artery (LAD), and proximal right coronary
J Pediatr. Author manuscript; available in PMC 2012 May 1.
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artery (RCA) were obtained by a standardized protocol and each echocardiogram was
interpreted in a core laboratory by a single observer who was blinded to subject and timing
of the study.
Laboratory data included a complete blood count, erythrocyte sedimentation rate (ESR),
albumin, alanine aminotransferase (ALT) and serum immunoglobulins (IgG, IgA, and IgM).
Baseline sodium, total bilirubin, and aspartate aminotransferase (AST) were also collected,
where available. Highly sensitive C-reactive protein (hsCRP) was measured in a core
laboratory.
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One subject (of 199 randomized) was excluded from analysis due to withdrawal shortly after
providing informed consent. We used the Wilcoxon rank sum test to compare the continuous
risk score distributions by IVIG retreatment status. We used the Fisher exact test and
Mantel-Haenszel test for linear trend to compare the categorical risk score (number of
points) distributions by IVIG retreatment status. Mixed model regression identified
associations between CA size and risk score over time. A treatment by IVIG retreatment risk
status interaction test from analysis of variance was used to assess whether baseline-adjusted
treatment effect on CA outcomes (the size of the steroid minus placebo difference) varied by
IVIG retreatment risk status (high vs. low). Treatment group was defined using actual
treatment received; two subjects assigned to the IVMP group did not receive IVMP and
were reclassified as placebo. Dimensions of the proximal LAD and proximal RCA were
adjusted for body surface area and expressed in standard deviation units (z scores) to assess
their size compared with the normal population and calculate the primary outcome,
maximum CA z-score.10 One- and five-week changes from baseline in maximum CA raw
dimension were also analyzed as outcomes. Secondary analyses excluding six patients who
were randomized but discovered to have met an exclusion criterion post hoc (two diagnosed
>Day 10; two with culture-proven virus; two received earlier steroid therapy) yielded
inferences similar to those in this report except where noted.

RESULTS
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Median time from fever onset to enrollment was 6 days (interquartile range, IQR, 6 to 8
days), and the median age was 2.9 years (IQR, 1.5 to 4.7 yrs). Fourteen percent were Asian.
IVIG retreatment was administered to 27 of the 198 (14%) subjects. Subjects retreated with
IVIG, compared with who were not retreated, were similar in age but were more likely to be
male (82% vs. 60%, p=0.03) and in univariate analysis of baseline laboratory variables
(Table I; available at www.jpeds.com), more likely to have a higher hsCRP (59% vs. 33% ≥
10 mg/dL), percentage of neutrophils ≥80% (23% vs. 8%, p=0.03), and bilirubin ≥0.9 mg/
dL (53% vs. 29%, p=0.03). Subjects retreated with IVIG also had lower platelet count
(median 32.9 vs. 39.4 × 104/mm3, p=0.005) and serum albumin concentration (2.9±0.6 vs.
3.4±0.6 g/dL, p<0.001) compared with those who were not retreated.
We explored multivariate predictive models for IVIG retreatment in our dataset (Table II).
In analyses including all study subjects, independent risk factors for IVIG retreatment
included male sex, lower albumin, and percentage of neutrophils ≥80% (c-statistic 0.77).
When we excluded the six trial-ineligible subjects who underwent randomization, only
lower albumin retained statistical significance (odds ratio=0.22, p<0.001), although the odds
ratios for male sex and neutrophils ≥80% both remained about three (p-values ≤0.12).
Because the previously published Japanese risk scores for prediction of IVIG retreatment
were derived from populations that did not receive primary steroid therapy, we also sought
to develop a model under comparable conditions. Using data restricted to subjects who did
not receive steroid therapy, the most consistent multivariate model included male sex, lower
albumin, and higher AST as independent risk factors for IVIG retreatment (c-statistic 0.83).

J Pediatr. Author manuscript; available in PMC 2012 May 1.
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Operating Characteristics of published scoring systems
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Complete data were available to calculate Kobayashi, Egami, and Sano risk scores for 115,
149, and 107 subjects, respectively (Table III; available at www.jpeds.com). The 83, 49, and
91 subjects without a Kobayashi, Egami, or Sano score, respectively, were similar to those
with a calculable score with respect to sex, age, number of illness days, baseline CA zscores, albumin, neutrophil count, and platelet count.
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Previously published Japanese risk scores for prediction of IVIG retreatment were derived
from populations that did not receive primary steroid therapy. Therefore, we explored the
operating characteristics of these risk scores using data from the trial subjects to whom
primary steroid therapy was not administered (Table IV). Within this subgroup, the median
Kobayashi scores for subjects with and without IVIG retreatment were median 2.0
(interquartile range, 1.0 to 4.0) vs. 1.0 (interquartile range, 0 to 3.0), respectively (p=0.14).
With high risk defined as ≥4, sensitivity was 33%, specificity was 87%, positive predictive
value was 30%, and negative predictive was value 87%. Thus, for example, if the Kobayashi
scoring system were applied to North American patients of mixed ethnicity to identify those
who might benefit from additional primary anti-inflammatory therapy (assuming that such
additional therapy was proven to have benefit), 30% of patients targeted as high risk would
receive additional therapy and might benefit; 70% targeted as high risk would receive
additional therapy without need, and 13% who received scores indicating low risk would not
receive additional therapy from which they might have benefited. Both the Egami and Sano
scores differed by IVIG retreatment status (p<0.05; Table IV), with sensitivity somewhat
higher compared with that of the Kobayashi score (42% and 40%, respectively).
Utility of risk scores in predicting coronary abnormalities
In the subjects not receiving primary steroid therapy, we examined the correlation between
CA z-scores at one- and five-weeks post-randomization and the three risk scores using
mixed model regression. The Kobayashi score was a significant predictor of CA z-scores for
all segments (mixed model p=0.01 to 0.04, independent of time point). However, the
associations were relatively weak; the largest Spearman correlation coefficient was 0.29,
between maximum CA z-score at one week and Kobayashi score. The Sano and Egami
scores were not associated with CA z-score. Similarly, none of the three risk scores were
associated at the 0.05 level with the paired change in raw coronary artery dimensions
(LMCA, proximal LAD or RCA) from baseline to one and five weeks later.
Efficacy of primary steroid therapy in reducing coronary abnormalities
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A post hoc subgroup analysis of the randomized trial suggested that, for subjects retreated
with IVIG only, CA outcomes were better among those initially treated with steroids
compared with those who received placebo (Figure). At five weeks post-randomization, in
patients who were retreated, CA size was one standard deviation smaller for patients treated
with steroids compared with those on placebo. However, in patients who were not retreated,
CA size did not differ significantly for the steroid and placebo groups.
We explored whether steroid treatment improved coronary outcomes in subjects whose
estimated risk of retreatment at baseline was high and found no significant interaction
between Kobayashi risk class (high vs. low) and steroid vs. no steroid treatment in
maximum CA z-score (p=0.23 and p=0.39 at one and five weeks, respectively), maximum
CA dimension, or change in maximum CA dimension from baseline. Of note, there were
clinically relevant baseline differences in maximum CA z-score by steroid treatment status
in each of the subgroups (high vs. low risk of IVIG resistance). Among the 17 patients
classified as high risk at baseline, mean maximum CA z-score at baseline was one standard
deviation lower in the steroid group compared with the placebo group. In the low-risk
J Pediatr. Author manuscript; available in PMC 2012 May 1.
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patients, mean baseline maximum CA z-score was 0.4 standard deviations larger in the
patients treated with steroids compared with the placebo group. After adjustment for
baseline differences, there was no evidence of a differential effect of steroid therapy in the
high and low risk subgroups (Figure; interaction p=0.68 at one week and p=0.68 at five
weeks). Similarly, when the Egami and Sano risk scores were each used to define risk status
for IVIG resistance, we found no significant interaction (p≥0.18) between risk class (high
vs. low) and primary treatment with steroid vs. no steroids in CA outcomes.

DISCUSSION
Using the dataset of the Pediatric Heart Network’s randomized, placebo-blind trial of pulsed
corticosteroids for primary therapy for KD, we evaluated the performance of three published
risk scoring systems for prediction of IVIG resistance, derived from the data of Japanese
populations1–3. The three scoring systems were developed using patients who did not
receive primary steroid therapy. We therefore performed our analyses both in the entire trial
cohort and within the group that received placebo plus conventional primary therapy with
IVIG and aspirin.
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We found that sensitivity of these risk scores was low (33–42%), and specificity was
moderate to high (85–87%). No differential treatment effect of steroids was found for
subjects classified as high vs. low risk for IVIG resistance based on these scores. Tremoulet
et al6 evaluated the Egami score using 362 children in San Diego county diagnosed with KD
in 2006 and found, similar to our report, low sensitivity (38%) and good specificity (84%) to
detect IVIG resistance. Our results suggest that use of Japanese scoring systems in a North
American population of mixed ethnicity will exclude most patients who are at low risk, but
will not capture the majority of those who may benefit from more intensive monitoring of
their condition and who may be the optimum candidates for additional therapies that may
interrupt the disease process.
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We used our dataset directly to identify correlates of IVIG resistance to better understand
why the existing Japanese risk score systems did not perform as well as expected in our
North American population. Male sex and albumin were two independent risk factors in our
placebo group, but none of the three existing risk scoring systems included these factors. It
is possible that IVIG resistance is a sex-linked trait, and that the conflicting importance of
sex as a risk factor in the Japanese datasets vs. a North American one reflects genetic
differences. In a retrospective analysis of children diagnosed with KD from 2002 to 2006,
Ashouri et al found low albumin, higher band counts, and a higher number of abnormal
echocardiography results independently predicted IVIG resistance11. However, this single
center study included a very small number of patients who were also in our analysis and
cannot be considered as independent support for our finding of low albumin as a risk factor.
Because IVIG non-responsiveness is associated with poor CA outcomes, we examined
whether the risk scores for IVIG resistance were correlated with maximum CA dimension
adjusted for body surface area (CA z-score) and found at most modest associations. Of note,
relatively few subjects in the Pediatric Heart Network trial developed clinically significant
CA abnormalities, so the power for detecting a relationship between CA outcomes and risk
scores was low. The reasons for the favorable CA outcomes in this cohort are unclear, but
could include an aggressive protocol for retreatment of IVIG resistance or the restriction of
eligibility for the trial to those with ≤10 days of fever.
The utility of a risk score for identification of the IVIG-resistant patient from baseline
clinical and laboratory variables would be to identify patients who might benefit for
adjunctive primary antiinflammatory therapies. The most extensively studied adjunctive

J Pediatr. Author manuscript; available in PMC 2012 May 1.
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therapy is corticosteroids. A recent meta-analysis of four randomized trials of primary
corticosteroid treatment in addition to IVIG and aspirin suggested that such treatment
decreased rates of IVIG re-treatment, although it was not shown to lower the risk of
coronary aneurysms or adverse events12. Information on the role of adjunctive primary
treatment with infliximab and etanercept await the results of ongoing trials.
Although primary treatment with pulsed corticosteroids did not improve CA outcomes
overall in the Pediatric Heart Network trial, a post hoc subgroup analysis suggested a
beneficial effect within the small group of children with IVIG resistance. In the current
analysis, we sought to determine whether patients predicted to be at high risk of IVIG
resistance had superior CA outcomes in response to the addition of primary corticosteroid
treatment to conventional therapy. We found no significant interaction of high vs. low risk
status by treatment received (steroid vs. placebo) using any of the three risk score
algorithms. Thus, we found no benefit of pulsed corticosteroid therapy on maximum CA
dimension in the subgroup of patients whose risk scores at presentation suggested a high
likelihood of IVIG resistance, and hence might have been preemptively identified as a
subgroup for whom additional treatment may have been targeted.
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The results of our analyses should be considered in light of certain limitations. Depending
on the risk scoring system used, 25–45% of subjects had insufficient data to calculate a
score, thus reducing statistical power. However, we found that subjects with missing scores
were similar to those who did have a score with respect to sex, age, number of illness days,
baseline CA zscores, and several laboratory measures, suggesting that exclusion of subjects
with missing scores imposed little bias. In addition, because patients were not randomly
assigned to steroid vs. placebo treatment within strata of predicted risk for IVIG resistance,
unmeasured factors between the low and high risk groups could account for our lack of a
differential steroid treatment benefit. Finally, our study did not include an independent
validation dataset to assess the reliability of the of the risk factors for IVIG resistance that
we identified. Furthermore, of the Japanese risk scoring systems, only the Kobayashi score
was validated.
In conclusion, risk scoring systems for IVIG resistance developed in Japan have low
sensitivity (<45%) and good specificity when applied to an independent dataset of North
American children. We were unable to demonstrate a benefit of primary steroid treatment
with prospective classification of patients into high vs. low risk for IVIG resistance using
published risk scores for IVIG resistance. Accurate prospective identification of North
American patients of mixed ethnicity at high risk for IVIG retreatment remains a challenge.
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Figure 1.

Baseline-adjusted Treatment Effect Estimates and 95% Confidence Interval by Actual IVIG
Retreatment Subgroup and by Estimated Kobayashi High vs. Low Risk Subgroup for
Maximum Coronary Artery Z-score at One and Five Weeks Post-Randomization
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IgG=Immunoglobulin G
IgA=Immunoglobulin A
IgM=Immunoglobulin M
ALT=Alanine aminotransferase
AST=Aspartate aminotransferase

p-value for proportions from exact test; p-value for continuous variables from Wilcoxon rank sum test except where noted with an asterisk to indicate t-test N represents the total available sample size for
the variable in each group.

*

25

IgG, median

27

27

27

104/mm3

Albumin, g/dL

Plaletets ≤ 30 ×

Platelets ×

104/mm3

27

NIH-PA Author Manuscript

Hemoglobin, g/dL

IVIG Retreated
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N
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Variable

Sleeper et al.
Page 10

J Pediatr. Author manuscript; available in PMC 2012 May 1.

Sleeper et al.

Page 11

Table 2

Multivariate Predictive Models for IVIG Resistance in the Pediatric Heart Network Kawasaki Disease Trial

NIH-PA Author Manuscript

Predictor

Odds Ratio

95%
Confidence
Interval

p-value

Model 1* All Subjects (N=180), c-statistic=0.77
Male sex

3.17

1.04, 10.75

0.04

Neutrophils≥80%

3.52

1.05, 11.85

0.04

Albumin, g/dL

0.21

0.08, 0.53

0.001

Model 2† No Steroid Therapy (N=72), c-statistic=0.83
Male sex

13.3

1.30, 143

0.03

Albumin, g/dL

0.20

0.05, 0.78

0.02

AST, IU/L

2.24‡

0.97, 5.16

0.06

*

When six trial ineligible subjects were excluded, only albumin was a significant predictor (odds ratio=0.22, p<.001). In the three-variable model
(N=174), the p-values for sex and neutrophils≥80% were 0.07 and 0.12, respectively.
†

NIH-PA Author Manuscript

*When the one trial ineligible subject who did not receive steroid therapy was excluded, the sex, albumin, and AST p-values were 0.03, 0.02, and
0.04, respectively.
‡

per 100 IU/L increase

IVIG=intravenous immunoglobulin
AST=aspartate aminotransferase
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Table 3

Published Risk Scoring Systems for IVIG Resistance for Japanese Subjects
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Score Component

Point
Assignment

KOBAYASHI (7 variables)
N=112 Resistant, N=434 Responsive
Low risk: 0–3; High Risk: ≥ 4
Sensitivity: 86%; Specificity: 67%;
PPV: 43%; NPV: 95%
AST ≥ 100

2

Sodium < 133 mmol/L

2

Fever Days ≤ 4

2

%Neutrophils ≥ 80

2

C-Reaction protein ≥ 10 mg/dL

1

Age ≤ 1 year

1

Plaletets ≤ 30 ×

104/mm3

1

NIH-PA Author Manuscript

EGAMI (5 variables)
N=41 Resistant, N=279 Responsive
Low Risk: 0–2; High Risk: ≥ 3
Sensitivity: 78%; Specificity: 76%;
PPV: 32%; NPV: 96%
ALT ≥ 80

2

Fever Days ≤ 4

1

C-Reactive protein ≥ 8 mg/dL

1

Age < 6 months

1

Plaletets ≤ 30 ×

104/mm3

1

SANO (3 variables)
N=22 Resistant, N=90 Responsive
Low Risk: 0–1; High Risk=2
Sensitivity: 77%; Specificity: 86%;
PPV: 59%; NPV: 94%

NIH-PA Author Manuscript

AST ≥ 200

1

Total Bilirubin ≥ 0.9 mg/dL

1

C-Reactive protein ≥ 7 mg/dL

1

ALT=Alanine aminotransferase
AST=Aspartate aminotransferase
PPV=Positive predictive value
NPV=Negative predictive value
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Table 4
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Distribution of Kobayashi, Egami, and Sano Risk Scores by IVIG Retreatment Status in Subjects who did not
Receive Steroid Therapy

N
Kobayashi Score†
Median score (IQR)

All

IVIG-Retreated

Not IVIGRetreated

62

9

53

1.7±1.6

2.4±1.9

1.5±1.6

1.0 (0, 3.0)

2.0 (1.0, 4.0)

1.0 (0, 3.0)

Kobayashi Score
29%

11% (1)

32% (17)

1

31%

33% (3)

30% (16)

2

11%

11% (1)

11% (6)

3

13%

11% (1)

13% (7)

4

8%

11% (1)

8% (4)

5

7%

22% (2)

4% (2)

NIH-PA Author Manuscript

2%

0.0%

2% (1)

Low Risk (0–3)

84%

67%

87% (specificity)

High Risk (≥ 4)

16%

33% (sensitivity)

13%

N
Egami Score†
Median score (IQR)

78

12

66

1.3±1.3

2.1±1.2

1.1±1.3

1.0 (0, 2.0)

2.0 (1.5, 3.0)

1.0 (0, 1.0)

Egami Score
35%

17% (2)

38% (25)

1

33%

8% (1)

38% (25)

2

13%

33% (4)

9% (6)

3

13%

33% (4)

9% (16)

4

4%

8% (1)

3% (2)

5

3%

0%

3% (2)

Low Risk (0–2)

81%

58%

85% (specificity)

High Risk (≥ 3)

19%

42% (sensitivity)

15%

56

10

46

0.9±0.8

1.5±0.7

0.8±0.8

1.0 (0, 1.0)

1.0 (1.0, 2.0)

1.0 (0, 1.0)

NIH-PA Author Manuscript

Sano Score†
Median score (IQR)

0.01

0.01, 0.02

0

N

0.14

0.40, 0.12

0

6

p-value*

Sano Score

0.03

0.03, 0.01

0

32%

0%

39% (18)

1

48%

60% (6)

46% (21)

2

16%

30% (4)

13% (6)

3

4%

10% (1)

2% (1)

Low Risk (0–1)

80%

60%

85% (specificity)

High Risk (2–3)

20%

40% (sensitivity)

15%

*

Wilcoxon rank sum test p-value for continuous score; Exact test and Mantel-Haenszel test for linear trend p-value for categorical distribution
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†

Mean±standard deviation

IQR = Interquartile range
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